Brain targeting of siRNA via intranasal pathway

Current Pharmaceutical Design

Volumn 21, Issue 31, 2015, Pages 4606-4613

  Mohanty, Chandana ^a   Kundu, Paromita ^a   Sahoo, Sanjeeb K ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN DISEASE; BRAIN ISCHEMIA; DRUG BIOAVAILABILITY; GENE SILENCING; GLIOBLASTOMA; HUNTINGTON CHOREA; NONVIRAL GENE DELIVERY SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; RNA INTERFERENCE; ANIMAL; BRAIN DISEASES; GENETICS; HUMAN; INTRANASAL DRUG ADMINISTRATION; METABOLISM; NANOTECHNOLOGY; PROCEDURES;

ADMINISTRATION, INTRANASAL; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN DISEASES; GENE SILENCING; HUMANS; NANOTECHNOLOGY; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84946771732     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282131151013191737     Document Type: Review

References (63)

1. Brasnjevic I, Steinbusch HW, Schmitz C, Martinez-Martinez P. Delivery of peptide and protein drugs over the blood-brain barrier. Prog Neurobiol 2009; 87: 212-251.
2. Sobocki P, Jönsson B, Wittchen H, Olesen J. Costs of disorders of the brain in europe. Eur J Neurol 2005; 12: 1-27.
3. Barchet TM, Amiji MM. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opin Drug Deliv 2009; 6: 211-225.
4. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 2009; 23: 35-58.
5. Pardridge WM. shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev 2007; 59: 141-152.
6. Goyal BR, Patel MM, Soni MK, Bhadada SV. Therapeutic opportunities of small interfering RNA. Fundam Clin Pharmacol 2009; 23: 367-386.
7. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010; 37: 48-57.
8. Illum L. Nasal drug delivery--possibilities, problems and solutions. J Control Release 2003; 87: 187-198.
9. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012; 64: 614-628.
10. Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv 2013; 10: 957-972.
11. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007; 59: 75-86.
12. Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med 2012; 85: 187-200.
13. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotech- nol 2004; 22: 326-330.
14. Deng Y, Wang CC, Choy KW, et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene 2014; 538: 217-227.
15. Broering R, Real CI, John MJ, et al. Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro. Int Immunol 2014; 26: 35-46.
16. Walid MS. Prognostic factors for long-term survival after glioblastoma. Perm J 2008; 12: 45-48.
17. Chang SM, Butowski NA, Sneed PK, Garner IV. Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme. Neurosurg Focus 2006; 20: E4.
18. Kanu OO, Hughes B, Di C, et al. Glioblastoma Multiforme Onco-genomics and Signaling Pathways. Clin Med Oncol 2009; 3: 39-52.
19. Kondo Y, Hollingsworth EF, Kondo S. Molecular targeting for malignant gliomas (Review). Int J Oncol 2004; 24: 1101-1109.
20. Sathornsumetee S, Reardon DA. Targeting multiple kinases in glioblastoma multiforme. Expert Opin Investig Drugs 2009; 18: 277-292.
21. Hu YY, Zheng MH, Zhang R, Liang YM, Han H. Notch signalling pathway and cancer metastasis. Adv Exp Med Biol 2012; 727: 186-198.
22. Raychaudhuri B, Vogelbaum MA. IL-8 is a mediator of NF-kappaB induced invasion by gliomas. J Neurooncol 2011; 101: 227-235.
23. Zanotto-Filho A, Braganhol E, Schroder R, et al. NFkappaB inhibitors induce cell death in glioblastomas. Biochem Pharmacol 2011; 81: 412-424.
24. Wang F, Bai HR, Wang J, Bai YZ, Dou CW. Glioma growth inhibition in vitro and in vivo by single chain variable fragments of the transferrin receptor conjugated to survivin small interfering RNA. J Int Med Res 2011; 39: 1701-1712.
25. Hendruschk S, Wiedemuth R, Aigner A, et al. RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol 2011; 13: 1074-1089.
26. Jin J, Bae KH, Yang H, et al. In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug Chem 2011; 22: 2568-2572.
27. Jensen RL. Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurg Focus 2006; 20: E24.
28. Gillespie DL, Aguirre MT, Ravichandran S, et al. RNA interference targeting hypoxia-inducible factor 1alpha via a novel multi- functional surfactant attenuates glioma growth in an intracranial mouse model. J Neurosurg 2014: 1-11.
29. Giacobini E, Gold G. Alzheimer disease therapy--moving from amyloid-beta to tau. Nat Rev Neurol 2013; 9: 677-686.
30. Chen S, Ge X, Chen Y, Lv N, Liu Z, Yuan W. Advances with RNA interference in Alzheimer's disease research. Drug Des Devel Ther 2013; 7: 117-125.
31. Rodriguez-Lebron E, Gouvion CM, Moore SA, Davidson BL, Paulson HL. Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease. Mol Ther 2009; 17: 1563-1573.
32. Singer O, Marr RA, Rockenstein E, et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 2005; 8: 1343-9.
33. Peng KA, Masliah E. Lentivirus-expressed siRNA vectors against Alzheimer disease. Methods Mol Biol 2010; 614: 215-224.
34. mouse brain by systemic injection of tar- geted exosomes. Nat Biotechnol 2011; 29: 341-345.
35. Huang HC, Jiang ZF. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. J Alzheimers Dis 2009; 16: 15-27.
36. Piedrahita D, Hernandez I, Lopez-Tobon A, et al. Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice. J Neurosci 2010; 30: 13966-13976.
37. Prasanthi JR, Larson T, Schommer J, Ghribi O. Silencing GADD153/CHOP gene expression protects against Alzheimer's disease-like pathology induced by 27-hydroxycholesterol in rabbit hippocampus. PLoS One 2011; 6: e26420.
38. Recasens A, Dehay B. Alpha-synuclein spreading in Parkinson's disease. Front Neuroanat 2014; 8: 159.
39. Lundberg C, Bjorklund T, Carlsson T, et al. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther 2008; 8: 461-473.
40. Liu YY, Yang XY, Li Z, et al. Characterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson's disease. CNS Neurosci Ther 2014; 20: 76-85.
41. Horvath L, van Marion I, Tai K, Nielsen TT, Lundberg C. Knock-down of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease. J Gene Med 2011; 13: 188-197.
42. Zhang Y, Friedlander RM. Using non-coding small RNAs to develop therapies for Huntington's disease. Gene Ther 2011; 18: 1139-1149.
43. Hu J, Liu J, Yu D, et al. Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs. Nucleic Acid Ther 2014; 24: 199-209.
44. Ross CA, Shoulson I. Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics. Parkinsonism Re- lat Disord 2009; 15 Suppl 3: S135-S138.
45. Miller JP, Holcomb J, Al-Ramahi I, et al. Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. Neuron 2010; 67: 199-212.
46. Fukuda AM, Badaut J. siRNA treatment: "A Sword-in-the-Stone" for acute brain injuries. Genes (Basel) 2013; 4: 435-456.
47. He Z, Ostrowski RP, Sun X, Ma Q, Huang B, Zhan Y, Zhang JH. CHOP silencing reduces acute brain injury in the rat model of su- barachnoid hemorrhage. Stroke 2012; 43: 484-490.
48. Ma Q, Manaenko A, Khatibi NH, Chen W, Zhang JH, Tang J. Vascular adhesion protein-1 inhibition provides antiinflammatory protection after an intracerebral hemorrhagic stroke in mice. J Cereb Blood Flow Metab 2011; 31: 881-893.
49. Kim HW, Cho KJ, Lee SK, Kim GW. Apoptosis signal-regulating kinase 1 (Ask1) targeted small interfering RNA on ischemic neu- ronal cell death. Brain Res 2011; 1412: 73-78.
50. Al-Jamal KT, Gherardini L, Bardi G, et al. Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing. Proc Natl Acad Sci USA 2011; 108: 10952-10957.
51. Kim ID, Lim CM, Kim JB, et al. Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain. J Control Release 2010; 142: 422-430.
52. Kim JB, Sig Choi J, Yu YM, et al. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 2006; 26: 6413-6421.
53. Kim ID, Shin JH, Kim SW, et al. Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol Ther 2012; 20: 829-839.
54. Hong CA, Nam YS. Functional nanostructures for effective delivery of small interfering RNA therapeutics. Theranostics 2014; 4: 1211-1232.
55. Gherardini L, Bardi G, Gennaro M, Pizzorusso T. Novel siRNA delivery strategy: a new "strand" in CNS translational medicine? Cell Mol Life Sci 2013; 71: 1-20.
56. Perez AP, Mundina-Weilenmann C, Romero EL, Morilla MJ. Increased brain radioactivity by intranasal P-labeled siRNA dendri- plexes within in situ-forming mucoadhesive gels. Int J Nanomed 2012; 7: 1373-1385.
57. Mohanty C, Das M, Kanwar JR, Sahoo SK. Receptor mediated tumor targeting: an emerging approach for cancer therapy. Curr Drug Deliv 2011; 8: 45-58.
58. Jhaveri AM, Torchilin VP. Multifunctional polymeric micelles for delivery of drugs and siRNA. Front Pharmacol 2014; 5: 77.
59. Kanazawa T, Akiyama F, Kakizaki S, Takashima Y, Seta Y. Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles. Bioma- terials 2013; 34: 9220-9226.
60. Kanazawa T, Morisaki K, Suzuki S, Takashima Y. Prolongation of life in rats with malignant glioma by intranasal siRNA/drug code livery to the brain with cell-penetrating peptide-modified micelles. Mol Pharm 2014; 11: 1471-1478.
61. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today 2008; 13: 144-151.
62. Casettari L, Illum L. Chitosan in nasal delivery systems for therapeutic drugs. J Control Release 2014; 190: 189-200.
63. Malhotra M, Duchesneau C, Saha S, Prakash S. Intranasal, siRNA Delivery to the Brain by TAT/MGF Tagged PEGylated Chitosan Nanoparticles. J Pharmaceutics 2013; 20: 1-10.